• CSPC Pharmaceutical Group secured Chinese regulatory approval for batoclimab injection, marketed as Enlida, from the National Medical Products Administration.
• The treatment is authorized alongside conventional drugs for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261023-12380628), on October 23, 2026, and is solely responsible for the information contained therein.